Objectives: This brain imaging study examines whether cognitively normal (NL) individuals with 2 parents affected by late-onset Alzheimer disease (LOAD) show evidence of more extensive Alzheimer disease pathology compared with those who have a single parent affected by LOAD.
Alzheimer disease (AD) is an age-related neurodegenerative disease and the most common form of dementia. Clinical studies indicate that by the time patients seek diagnosis, the amount of irreversible brain damage that may have already occurred hinders treatment potential. Effective interventions, as they become available, ideally would be implemented in at-risk individuals before symptoms occur.
Having a family history (FH) of AD is a major risk factor for developing the disease. 1, 2 While the rare early-onset forms of AD (EOAD) have autosomal dominant genetic inheritance, the risk of developing late-onset AD (LOAD) (i.e., .99% of the AD population older than 60 years) is influenced by genetic and nongenetic factors. 1 Although LOAD does not show recognizable mendelian inheritance, risk is to some extent genetically determined, as shown by the familial aggregation of many cases. 2 Among probands, those with a parent affected by LOAD are at particularly high risk, 3, 4 and the risk is higher still when both parents are affected. [5] [6] [7] However, because only ,5% of individuals have both parents affected by LOAD, 2,5-7 the clinical profile associated with this rare circumstance has been poorly studied and epidemiologic findings have not been characterized by the use of biomarkers.
Many studies indicated that b-amyloid (Ab) dysmetabolism is a primary event in the pathogenesis of EOAD. 8 Fibrillar Ab deposition in senile plaques is a cardinal neuropathologic feature in AD and develops many years before clinical symptoms. 9 However, because many cognitively normal (NL) elderly show Ab pathology, 10 its functional significance is unclear. It remains to be established whether Ab accumulation is also an early event in LOAD. 1 Previous brain imaging studies have shown that, among NL individuals who have parents with LOAD, those with maternal FH (FHm) present with increased Ab load on 11 C-Pittsburgh compound B (PiB)-PET, 11, 12 progressive glucose metabolism reductions on 18 F-fluoro-2deoxyglucose (FDG)-PET, 13, 14 and gray matter volume (GMV) loss on MRI [15] [16] [17] [18] in the same regions as those with clinical AD. In contrast, NL individuals with paternal FH (FHp) are far less likely to show biomarker abnormalities. 11, [13] [14] [15] [16] [17] [18] There are no biomarker studies that examined NL individuals with maternal and paternal FH (FHmp).
The present multimodality brain imaging study used voxel-based techniques such as statistical parametric mapping, voxel-based morphometry (VBM), and z-score mapping to simultaneously examine Ab deposition, glucose metabolism, and GMV to test whether NL FHmp show more severe biomarker abnormalities than those with one affected parent.
METHODS Subjects. This study included 52 clinically and cognitively NL individuals enrolled in longitudinal studies at New York University School of Medicine. These included individuals interested in research participation and risk consultation and family members and caregivers of patients with AD. Subjects received medical, neuropsychological, and brain imaging examinations within 6 months. Individuals with medical conditions or history of conditions that may affect brain structure or function, i.e., stroke, diabetes, head trauma, any neurodegenerative diseases, depression, hydrocephalus, intracranial mass, and infarcts on MRI, and those taking psychoactive medications were excluded. Subjects were 32 to 72 years of age, with education $12 years, Clinical Dementia Rating score 5 0, Global Deterioration Scale scores #2, Mini-Mental State Examination scores $28, Modified Hachinski Ischemia Scale scores ,4, and normal cognitive test performance. 11, 13 An FH of LOAD that included at least one first-degree relative whose AD onset was after age 60 years was elicited by using standardized questionnaires. 11, 13 The information was confirmed with other family members by interview with the examining physician. Only individuals whose parents' diagnosis of LOAD was reportedly clinician certified and whose parents had lived to age 65 years or older were included. Subjects were divided into 4 demographically balanced groups of 13 subjects each, including FHm, FHp, FHmp, and controls with negative FH of any dementia (FH2). Thirteen FHmp participants completed all procedures. Among the larger pool of participants, we selected 13 FHm, FHp, and FH2 subjects who were balanced for demographical characteristics to the FHmp group. Specifically, all of the FHm and FH2, and 11 FHp subjects were individually matched to the FHmp subjects for age (within 3 years), sex, and education. The remaining 2 FHp subjects were matched to the FHmp group for their mean age and educational level (table 1). The AD-affected parents of 4 subjects (1 FHmp, 2 FHm, and 1 FHp) received the postmortem diagnosis of AD.
Standard protocol approvals, registrations, and patient consents. All subjects signed informed consent to participate in this institutional review board-approved study.
Brain imaging. All subjects received volumetric 1.5-tesla MRI (124-slice, T1-weighted, fast gradient echo, 1.2-mm sections, no interslice gaps), PiB-PET, and FDG-PET scans following standardized procedures. [11] [12] [13] [14] 16 For PET, subjects were positioned in the scanner 60 minutes postinjection of 15 mCi of 11 C-PiB, and scanned for 30 minutes in 3-dimensional mode on an LS Discovery or BioGraph PET/CT scanner. 12 The FDG scan was performed 30 minutes after completion of the PiB scan or on a separate day. After an overnight fast, subjects were injected with 5 mCi of FDG, positioned in the scanner 35 minutes postinjection, and scanned for 20 minutes. All images were corrected for photon attenuation, scatter, and radioactive decay and smoothed for uniform resolution. 19 For each subject, summed PET images corresponding to 40 to 60 minutes of FDG data and 60 to 90 minutes of PiB data were coregistered to MRI using the normalized mutual information routine of statistical parametric mapping (SPM8). 20 Parametric standardized uptake value ratio images were generated by normalizing PiB uptake by cerebellar gray matter (GM) uptake 21 and FDG by pons activity. 22 MRIs were segmented into GM, white matter, and CSF and normalized to Montreal Neurological Institute (MNI) space by high-dimensional warping (DARTEL) using VBM8. 20 PET scans were corrected for partial volume (PVC) effects. 23 MRI-coregistered raw and PVC FDG and PiB scans were spatially normalized using subject-specific transformation matrixes obtained from MRI, and smoothed with a 10-mm full width at half maximum (FWHM) filter.
MRIs were examined using VBM. 20, 24 A custom template was created using MRI from all subjects by normalizing and segmenting the MRIs using the unified segmentation model with the MNI template and tissue probability maps (TPMs), and averaging the normalized subject TPMs. Individual scans were then processed using the custom TPMs. Jacobian modulation was applied to restore absolute GMVs in the GM images, which were smoothed with an 8-mm FWHM kernel. Total GM, white matter, CSF, and intracranial volumes (TIV) were calculated.
Statistical analysis. SPSS version 19 (IBM Corp., Armonk, NY)
and SPM8 were used for analysis. Clinical and demographic measures were examined with the general linear model and x 2 tests. A full factorial model with post hoc linear t-contrasts was used to test for regional differences in GMV, raw and PVC PiB and FDG across groups. We first compared the combined FHmp, FHm, and FHp groups (FH1) vs FH2, and then tested for differences across FH1 groups and vs FH2. No proportional scaling was performed because PET scans were normalized to reference regions, and GMV images were corrected for TIV. Including TIV as a covariate left results substantially unchanged. Age and APOE genotype were examined as covariates. Analyses were repeated in a subset of subjects aged 60 years or younger.
Spatially normalized MRI and PVC PiB and FDG images were used to create z-score maps for each subject against controls, to directly compare the degree of Ab load, hypometabolism, and GMV loss. 25 The z-score maps were examined with paired t tests across all subjects and within groups.
Because we had specific a priori hypotheses on which brain regions would show possible biomarker effects, results were examined at p , 0.001, uncorrected (cluster extent $20 voxels, i.e., $2 times the FWHM), 20 [11] [12] [13] [14] 16 Anatomical location of brain regions showing significant effects was described using Talairach and Tournoux coordinates, after conversion from MNI space.
RESULTS Clinical characteristics of the subjects under study are found in table 1. There were no group differences in clinical and neuropsychological measures, APOE status, and age at onset of the affected parents (table 1) .
On MRI, the FHmp group showed reduced GMV in temporal cortex and striatum compared with FH2 and FHm groups, and in parietal and frontal regions compared with FHp and FHm groups (p , 0.001; figure 1 , table e-1 on the Neurology ® Web site at www.neurology.org). Both FHm and FHp groups showed reduced GMV in precuneus compared with FH2, and the FHm group showed additional GMV reductions in parietal cortex vs FHp (p , 0.001; figure 1 , table e-1). Overall, GMV reductions were most pronounced in FHmp and intermediate in FHm and FHp vs controls (figure 2). Analysis of whole-brain volumes extracted from VBM confirmed that FHmp had reduced GMV compared with FH2 (p , 0.05), while there were no significant differences for FHm and FHp (table 1) .
On PiB-PET, before and after PVC, the FHmp group showed increased PiB retention in frontal and parietal regions and striatum compared with FH2 and FHp groups (p , 0.001; figure 1 , table e-2). PiB accumulation tended to be more severe than in FHm in regard to the number of regions affected and magnitude of impairment (figures 1 and 2, table e-2), although the effect was marginally significant (p # 0.01). The FHm group showed increased PiB retention in frontal regions compared with FH2 and FHp, and in additional temporal regions compared with FHp (p , 0.001; figure 1 , table e-2). Overall, PiB retention was highest in FHmp, intermediate in FHm, and lowest in FHp and controls (figures 1 and 2).
On FDG-PET, both FHmp and FHm groups showed reduced FDG uptake in posterior cingulate, precuneus, and temporal regions compared with FH2, and in frontal regions compared with FHp (p , 0.001; figure 1 , table e-3). Hypometabolism was more extended in FHmp than in FHm (figure 1). Metabolic reductions in FHmp vs the other groups remained significant after PVC, as did frontal hypometabolism in FHmp and FHm vs FHp (p , 0.001). Overall, FDG uptake was lowest in FHmp, intermediate in FHm, and highest in FHp and controls ( figure 2) .
For all analyses, no brain regions showed biomarker abnormalities in FHp or FH2 vs the other groups, or in FHm and FHp vs FHmp. For all modalities, results remained substantially unchanged accounting for age and APOE status.
Analysis was repeated in the 36 NL individuals aged 60 years or younger, including 9 subjects per group who were matched by age (in all groups, mean age 5 50 6 7 years), sex (6 women), and education (17 6 2 years), and there were 4 APOE e4 carriers in each group. Results were substantially unchanged from those in the entire group, with FHmp subjects showing the most severe abnormalities (p , 0.001; figure 3 ).
On paired t tests of z-score images, there were no regions showing evidence of one biomarker abnormality exceeding that of the others in the FH2 control group. Across all FH1 subjects, the extent of PiB load exceeded that of GMV reductions in medial and orbitofrontal cortex and parietotemporal regions, and exceeded that of FDG hypometabolism in medial frontal cortex, inferior temporal areas, precuneus, and striatum (p , 0.001; figure 4 ). Hypometabolism exceeded GMV reductions in parietotemporal and lateral frontal cortices, and exceeded PiB retention in some smaller clusters located in parietotemporal regions. GMV reductions exceeded hypometabolism in left caudate (p , 0.001; figure 4 ). There were no brain regions in which the extent of GMV reductions exceeded that of PiB retention. Overall, PiB abnormalities exceeded those of the other biomarkers in magnitude and in size ( figure 4) . Specifically within each FH group, pattern results were essentially indistinguishable from the entire sample, with the exception that in the FHm group there were no regions in which the extent of PiB retention exceeded that of hypometabolism (p , 0.001; figure 4) . DISCUSSION There is a paucity of studies in FHmp. The few published epidemiologic studies showed that children of 2 parents affected by LOAD have higher lifetime risk of AD than NL individuals with one affected parent or no affected parents, 5-7 by virtue of carrying a higher burden of yet unknown biological risk factors. However, these studies compared FHmp either with FH2 or with a combined group of individuals with one AD parent, neglecting possible risk differences between maternal and paternal transmission. [5] [6] [7] Our results provide biological evidence for the hypothesized "parent-dose effect" on LOAD risk by showing a novel association between established AD biomarkers and a double parental history of LOAD. NL FHmp presented with co-occurring increased Ab burden, hypometabolism, and GMV loss in the same brain regions as in clinical AD, 10 which were more pronounced vs NL with one LOAD parent and vs controls regarding the number of regions affected and magnitude of impairment.
Additionally, there were significant parent-sex effects. NL FHmp showed the highest degree of biomarker abnormalities, followed by NL FHm at intermediate levels of pathology, while FHp showed the lowest degree of impairment. Thus, FHmp status confers the highest amount of presumed risk, but FHm status also confers greater risk to the offspring than FHp status. These data are consistent with epidemiologic and biomarker findings that maternal transmission is associated with higher risk than paternal transmission, independent of increased female longevity. 2, 11, [13] [14] [15] [16] [17] [18] [26] [27] [28] [29] [30] [31] Present findings expand on prior unimodality biomarker studies showing multiple biomarker deficits in NL FHm, which appeared to be overall less severe than in FHmp. Interestingly, NL FHm was the only group in which Ab load did not significantly exceed hypometabolism. While this could be attributable to the small sample, it is possible that other mechanisms, such as maternally transmitted mitochondria bioenergetics deficits, may account for this finding. 2 The neuropathologic changes of AD are known to precede the clinical expression of disease by many years. 8 The presence of altered biomarkers in relatively young NL FHmp, and to a lesser extent FHm and FHp, suggests that these brain abnormalities had begun at even younger ages. The degree and extent of Ab load exceeded that of the other biomarkers, suggesting that Ab pathology may, at least in part, account for FDG and MRI deficits in NL FHmp. PiB-PET abnormalities are known to be predictive of future AD. [32] [33] [34] However, present cross-sectional results do not offer information on the temporal order in which biomarker alterations occur or on how one biomarker influences the other.
Longitudinal follow-up studies and larger samples are necessary to determine whether the observed biomarker abnormalities are predictive of future dementia, and according to parental dose.
PiB-PET studies of presymptomatic EOAD have shown that Ab accumulates early in the striatum of mutation carriers, and to a lesser extent in neocortex. 35 Ab deposition in our NL FH1 was more prominent in cortical than subcortical regions, supporting the idea of different Ab deposition patterns in EOAD and LOAD. 8, 35 Previous PET studies showed altered AD biomarkers in NL carriers of the APOE e4 allele, a major LOAD genetic risk factor. 36, 37 APOE allelic variations occur in all individuals, and genotypes can be established at any age. In comparison, NL FHmp do not exist in great numbers because this rare condition occurs in ,5% of individuals. 2, [5] [6] [7] Moreover, it is particularly challenging to find young FHmp because the parents also need to be old enough to have developed dementia. To our knowledge, there are no prior imaging studies that were able to recruit such a cohort. Despite a smaller sample, we were able to show clear biomarker differences across groups, and also to recruit a sufficient number of subjects to repeat the analysis in a subset of 36 NL individuals aged 60 years or younger, which showed that the younger FHmp still had higher Ab burden than the other groups. Results were independent of APOE genotype, and only 30% of our subjects were e4 carriers. Unfortunately, the small sample precludes analysis of interactions between FH and APOE genotypes. Descriptively, APOE genotypes did not seem to be the main determinants of biomarker abnormalities by FH group (figure e-1). The FHmp group showed more severe biomarker abnormalities vs other groups despite including slightly more APOE e3/e2 carriers, who presumably carry lower risk of AD. 1 FHmp included 2 e4/e4 and 2 e3/e4 carriers, while FHm and FHp groups both included one e4/e4 but 1 or 2 additional e3/e4 carriers (table 1) . As such, it is not possible to make inferences about the contribution of different APOE genotypes to current results. Additionally, the APOE e4 genotype has been associated with an earlier age at onset of AD, 1 whereas the age at onset of the AD parents was comparable across groups, further indicating lack of substantial APOE-related effects in our cohort. However, we do not have information on the parents' APOE genotypes. Because a clear relationship was shown among age, APOE, and Ab deposition, 38 studies with larger samples are needed to determine how each genotype relates to AD biomarkers in combination with FH, as well as in probands and their parents.
Steps were taken to ensure that the AD diagnosis in the subjects' parents was accurate. An FH of LOAD was elicited using standardized questionnaires that are known to have good agreement with neuropathologic findings. 39 Nonetheless, our cohort may have included subjects whose parents did not have AD but another dementia. This would lead to inclusion of subjects with lower risk of AD in the FH1 groups, conservatively reducing power in detecting group differences. While we only included subjects whose parents had lived to age 65 years or older, our cohort may have included subjects whose parents had passed away before developing dementia or any APOE-related features. However, this would lead to inclusion of subjects with higher risk of AD among controls, or to including an FHmp subject in the FHm or FHp group, also reducing power to detect group differences.
We caution that the NL population selected in our study represents a group with a high a priori risk of preclinical AD changes, and results were made with small numbers of carefully screened subjects under controlled clinical conditions. Replication of these preliminary research findings in community-based populations is warranted and clinical application is not justified. 
AUTHOR CONTRIBUTIONS

STUDY FUNDING
Supported by National Institute on Aging grants AG035137, AG13616, AG032554, and AG022374, and Alzheimer's Association grant IIRG-09-132030.
DISCLOSURE
L. Mosconi has a patent on a technology that was licensed to Abiant Inc. by NYU and, as such, has a financial interest in this license agreement and holds stock and stock options on the company. Dr. Mosconi has received compensation for consulting services from Abiant Inc. J. Murray reports no disclosures. W. Tsui has a patent on a technology that was licensed to Abiant Inc. by NYU and, as such, has a financial interest in this license agreement and holds stock and stock options on the company. Y. Li has received compensation for consulting services from Abiant Inc. N. Spector, A. Goldowsky, S. Williams, and R. Osorio report no disclosures. P. McHugh was principal investigator (PI) on an investigator-initiated clinical trial supported by Bayer Healthcare Pharmaceuticals. L. Glodzik has received honoraria from the French Alzheimer's Foundation and was PI on an investigator-initiated clinical trial supported by Forest Labs. S. Vallabhajosula reports no disclosures. M. de Leon has a patent on a technology that was licensed to Abiant Inc. by NYU and, as such, has a financial interest in this license agreement and holds stock and stock options on the company. Dr. de Leon has received compensation for consulting services from Abiant Inc., has received honoraria from the French Alzheimer's Foundation, and was PI on an investigator-initiated clinical trial supported by Neuroptix. Go to Neurology.org for full disclosures.
